Today's Date: March 18, 2024
Carlisle Companies to Acquire MTL Holdings, a Leader in Edge Metal and Non-Insulated Architectural Wall Systems   •   Statement by Minister Qualtrough on the Closing of the 2024 Arctic Winter Games in the Mat-Su Valley, Alaska   •   Smarter AI for All: Lenovo Unveils Hybrid AI Solutions that Deliver the Power of Tailored Generative AI to Every Enterprise and   •   Using Banuba SDKs Gives Businesses an Advantage in the Case of TikTok Ban   •   Mbanq and The Financial Policy Council to Host: “Business Banking Battles – Big Value in the Face of Bank Industry T   •   NAREB PREPARES MEMBERS FOR MAJOR CHANGES TO HOME SALES AGENT COMMISSIONS AFTER LAWSUIT SETTLEMENT   •   SBS TO RECEIVE MULTIMILLION DOLLAR SETTLEMENT FROM VOZ MEDIA   •   Cadence and NVIDIA Unveil Groundbreaking Generative AI and Accelerated Compute-Driven Innovations   •   New ASEAN Energy and ACTUAL Sign Cooperation Agreement to Develop Net-Zero Plan for the New $5B USD Pengerang Energy Complex   •   UL Solutions and SINAI Technologies Join Forces to Help Customers Enhance Decarbonization and ESG Performance and Reporting   •   Consumers Energy Expands MI Clean Air, Allowing Customers to Offset Carbon Emissions   •   Mitsubishi Electric Named to CDP Supplier Engagement Leader   •   College of Saint Mary Selects YuJa Enterprise Video Platform as Campuswide Media Creation and Distribution Solution   •   UNLOCK SPRING LEARNING: THE TOY ASSOCIATION™'S NEW STEAM ACCREDITED TOY LIST OFFERS 25 ENGAGING TOYS FOR KIDS   •   Hyundai Showcases Refined-Rugged SUV Experience in New Asian American Campaign for the All-New Santa Fe   •   TM Associates Announces Grand Opening of Luxury Affordable Apartment Community in DC, MDXL Flats Apartments   •   EverWind Fuels Praises Historic Canada-Germany Agreement to Sell Canadian Green Hydrogen   •   EarthX to Feature Benji Backer, Author of "The Conservative Environmentalist," at Upcoming Congress of Conferences   •   Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant   •   Spire Global to Enhance AI-Driven Weather Prediction in Collaboration with NVIDIA
Bookmark and Share

Mycovia Pharmaceuticals CEO Patrick Jordan Named 2020 Life Sciences CEO of the Year by Triangle Business Journal

DURHAM, N.C. , August 06 /Businesswire/ - Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced Chief Executive Officer, Patrick Jordan, was named Life Sciences CEO of the Year by the Triangle Business Journal (TBJ). The prestigious regional TBJ Life Sciences Awards recognize individuals and research organizations that are blazing trails and breaking ground in the life sciences field. Mr. Jordan will be featured along with other winners in a special section of TBJ’s August 21 issue.

Mr. Jordan receives this award following an important year for Mycovia in which the company achieved multiple milestones in the development of its lead product candidate, oteseconazole, a novel oral therapy being studied for the treatment of recurrent vulvovaginal candidiasis (RVVC). The company completed enrollment ahead of schedule for its global phase 3 studies conducted in 11 countries, closed two transformational licensing agreements with Hengrui Medicine and Gedeon Richter, and was named the “Buzz of BIO” Late Stage Leader by the world’s largest biotech trade organization. Patrick has also recently led conversations with other industry executives about the need for increased investment for research and development in women’s health, including participating in panels at BIO-Europe 2019 last October and BIO Digital 2020 in June.

As CEO, Mr. Jordan leads Mycovia in its community involvement efforts. Over the past year, Mycovia has contributed to various initiatives in the Triangle, including supporting a local Durham elementary school with a BackPack Buddies program, instituting a company-wide employee volunteer day and sponsoring a triathlon event in Chapel Hill in October 2019 hosted by Ramblin’ Rose/Girls on the Run of the Triangle.

Mr. Jordan shared his thoughts on receiving this recognition, “I am deeply honored to receive this award and dedicate it to an outstanding team at Mycovia. This team inspires me through its passion, enlightens me with its insights, emboldens me by its courage, and drives me with its commitment. It is my genuine privilege to work together with this team to advance new therapies to address overlooked conditions affecting millions of people globally.”

About Mycovia Pharmaceuticals

Mycovia Pharmaceuticals has a passion for developing breakthrough therapies in areas of unmet medical need, with an initial focus in women’s health. Our lead product candidate, oteseconazole (VT-1161), is a novel, oral therapy for RVVC, that is designed with the goal of having greater selectivity, fewer side effects and improved efficacy. While not yet approved by the FDA, oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations to support its potential to be the first FDA-approved treatment for RVVC. Oteseconazole is currently in Phase 3 clinical trials designed to establish its safety and efficacy in RVVC patients. In 2019, Mycovia licensed oteseconazole to Jiangsu Hengrui Medicine Co., to develop and commercialize oteseconazole in China, including mainland China, Hong Kong, Macau and Taiwan, and Gedeon Richter Plc., a Hungary-based pharmaceutical company, to commercialize and manufacture oteseconazole in Europe, Russia, the Commonwealth of Independent States, Latin America and Australia. Mycovia also recognizes a tremendous potential for its oral fungal inhibitors and a growing need to treat a range of multi-drug resistant fungal pathogens. For more information, please visit www.mycovia.com.

About Recurrent Vulvovaginal Candidiasis

RVVC is a debilitating, chronic infectious condition that affects millions of women. Primary symptoms include vaginal itching, burning, irritation and inflammation. Some women may experience abnormal vaginal discharge and painful sexual intercourse or urination, causing variable but often severe discomfort and pain. RVVC impacts quality of life, to a degree comparable to asthma and worse than diseases such as migraine.


STORY TAGS: Science, Women, Biotechnology, Research, Pharmaceutical, Health, Consumer, Clinical Trials, North Carolina, United States, North America, Personnel, Award,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News